Opportunity Information: Apply for HRSA 11 031
Apply for HRSA 11 031
- The Health Resources and Services Administration in the health sector is offering a public funding opportunity titled "Sickle Cell Disease and Newborn Screening Program and National Coordination and Evaluation Center" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.110 Maternal and Child Health Federal Consolidated Programs.
- This funding opportunity was created on Nov 30, 2010 and posted on Nov 20, 2010.
- Applicants must submit their applications by Jan 18, 2011. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $3,500,000.00 to eligible and selected applicants.
- Each selected applicant is eligible to receive up to $700,000.00 in funding.
- The number of recipients for this funding is limited to 7 candidate(s).
- Eligible applicants include: Others (see text field entitled Additional Information on Eligibility for clarification).
- Project 1 Eligible entities must be a national organization with the capacity, capability, expertise and knowledge of sickle cell disease and other hemoglobinopathies to support HRSA funded grantees in a life course approach to services. Project 2 Eligible entities must be an organization with the capacity, capability, expertise and knowledge of sickle cell disease and other hemoglobinopathies, able to deliver a life course approach to services for affected individuals and families. Programs receiving funding for the Sickle Cell Disease Treatment Demonstration Program (SCDTDP) are not eligible to apply As cited in 42 CFR Part 51a.3 (a), any public or private entity, including an Indian tribe or tribal organization (as those terms are defined at 25 U.S.C. 450(b)), is eligible to apply for this federal funding. Under the president s initiative, community based and faith based organizations that are otherwise eligible and believe they can contribute to HRSA s program objectives are urged to consider this initiative. Additional eligibility requirements will be included in the application materials.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Health Resources and Services Administration (HRSA) grant opportunity titled "Sickle Cell Disease and Newborn Screening Program and National Coordination and Evaluation Center" (Funding Opportunity Number HRSA-11-031) is a discretionary cooperative agreement program created to improve how sickle cell disease (SCD) and other hemoglobinopathies are identified, followed, and managed from birth through adulthood. The central idea is a "life course" approach, meaning applicants are expected to think beyond isolated services or a single age group and instead build connected systems that support individuals and families at every stage of life. Although the initiative emphasizes people who have SCD or are carriers of sickle cell, it explicitly includes other hemoglobinopathies, with thalassemia specifically referenced as an example. A major priority throughout the announcement is reaching and serving emerging populations, which generally refers to populations that are newly growing or newly identified in certain communities and may be less connected to traditional specialty care networks.
HRSA planned to make seven total awards under this opportunity, split into two related projects. Project 1 funds up to six community-based cooperative agreements intended to demonstrate model systems of comprehensive care and medical management for people and families affected by, or at risk for, SCD and other hemoglobinopathies. These models are expected to be broad and integrated, tying together newborn screening and follow-up with diagnosis, counseling, education, and referral pathways into health care and supportive services. A key expectation is that programs address continuity of care across transitions, especially the transition from pediatric to adult health care providers, which is often a high-risk gap for people living with SCD. Another repeated emphasis is strengthening the "medical home" concept, meaning care that is coordinated, patient- and family-centered, and connected to appropriate specialty services, rather than fragmented across multiple unconnected providers and settings.
Project 1 also places strong weight on collaboration and shared leadership across stakeholders. HRSA describes an ideal model as a partnership among patients, families, and professionals, linking individuals with hemoglobin disorders, family groups, state newborn screening programs, community-based organizations, hemoglobinopathy treatment centers, primary care providers, medical home settings, and public health organizations. In practice, this points toward a networked service model where education, screening follow-up, clinical management, and social supports are deliberately coordinated, and where outreach strategies are designed to bring in emerging populations who may face language, cultural, geographic, insurance, or system-navigation barriers.
Project 2 establishes a single National Coordination and Evaluation Center (NCEC) that is meant to serve as the national backbone for coordination, implementation support, and evaluation across the HRSA-funded programs. The NCEC is designed to help overcome common challenges that occur after newborn screening, including ensuring timely follow-up, connecting families to accurate information and services, and reducing barriers to needed health and genetic services. The center is expected to work directly with HRSA-funded SCD and hemoglobinopathy programs to improve shared learning and quality. The announcement spells out four main NCEC responsibilities: increasing hemoglobinopathy knowledge among affected individuals and families (from birth across the lifespan) and among providers served by the community-based programs; strengthening partnerships between HRSA-funded programs, community organizations, and other relevant partners; supporting outreach and education efforts aimed at emerging populations; and improving the overall quality of hemoglobinopathy services and activities delivered through the HRSA-funded network.
From a funding and administrative standpoint, this is a cooperative agreement, which generally indicates substantial federal involvement in guiding or partnering on program activities compared with a standard grant. HRSA estimated total program funding at $3,500,000, with individual awards ranging from a floor of $100,000 to a ceiling of $700,000. Cost sharing or matching is not required. The program fell under CFDA 93.110 (Maternal and Child Health Federal Consolidated Programs). HRSA posted the opportunity on November 20, 2010, with an application closing date of January 18, 2011, and it was later archived on March 19, 2011.
Eligibility is described broadly but with project-specific expectations and one notable exclusion. The announcement references that, under 42 CFR Part 51a.3(a), any public or private entity, including Indian tribes or tribal organizations, may apply, and it encourages community-based and faith-based organizations to consider applying if they can contribute to HRSA's objectives. However, additional eligibility requirements were to be included in the application materials, and the summary includes project-level descriptions of the type of capacity expected. For Project 1, eligible entities are described as national organizations with the capacity, expertise, and knowledge of SCD and other hemoglobinopathies to support HRSA-funded grantees using a life course approach. For Project 2, eligible entities must similarly have the capacity and expertise to deliver a life course approach for affected individuals and families. The opportunity also states that programs already receiving funding under the Sickle Cell Disease Treatment Demonstration Program (SCDTDP) are not eligible to apply, which is meant to prevent duplication and keep this initiative focused on new or distinct program capacity.
Overall, this opportunity is best understood as a two-tier structure: community-based demonstration projects that build and test comprehensive, lifespan-oriented care networks (Project 1), supported and aligned nationally by a coordination and evaluation hub that strengthens partnerships, spreads knowledge, improves quality, and helps reduce screening-to-care gaps (Project 2). The intended impact is a more reliable, connected pathway from newborn screening through ongoing care, with deliberate attention to counseling, education, access, and the practical barriers that often prevent families and providers from getting the right services at the right time, especially in emerging populations.
Frequently Asked Questions (FAQs)
What is the purpose of the HRSA grant opportunity HRSA-11-031?
The opportunity funds cooperative agreements designed to improve how sickle cell disease (SCD) and other hemoglobinopathies are identified, followed, and managed from birth through adulthood. The program emphasizes building connected systems of screening follow-up, counseling, education, referrals, and ongoing medical management so individuals and families have a clearer pathway from newborn screening into appropriate services across the lifespan.
What is meant by a "life course" approach in this program?
A life course approach means applicants are expected to think beyond isolated services or a single age group and instead build coordinated systems that support people and families at every stage of life, from newborn screening and early childhood through adolescence, transition years, and adulthood.
Which conditions are included under this funding opportunity?
The program focuses on sickle cell disease and people who are carriers of sickle cell, and it explicitly includes other hemoglobinopathies. Thalassemia is specifically referenced as an example of another hemoglobinopathy included.
Who is the program intended to serve?
The program is intended to support individuals and families affected by, or at risk for, SCD and other hemoglobinopathies. It also places special priority on reaching emerging populations, meaning populations that are newly growing or newly identified in certain communities and may be less connected to established specialty care networks.
What are "emerging populations" in the context of this opportunity?
Emerging populations generally refers to communities that are newly growing or newly identified in certain areas and may have less connection to traditional hemoglobinopathy specialty care networks. The announcement highlights the need for outreach strategies that address barriers such as language, cultural differences, geography, insurance, and difficulty navigating health systems.
How many total awards did HRSA plan to make under this opportunity?
HRSA planned to make seven total awards, split across two related projects: up to six awards for community-based demonstration programs (Project 1) and one award for a National Coordination and Evaluation Center (Project 2).
What is Project 1 under this opportunity?
Project 1 funds up to six community-based cooperative agreements intended to demonstrate model systems of comprehensive care and medical management for people and families affected by, or at risk for, SCD and other hemoglobinopathies. These models are expected to integrate newborn screening and follow-up with diagnosis, counseling, education, referral pathways, and connections to supportive services.
What kinds of activities are expected in Project 1 model systems?
Project 1 models are expected to connect key elements including newborn screening follow-up, diagnosis, counseling, education, and referral pathways into health care and supportive services. A recurring expectation is continuity of care across life stages, especially during the transition from pediatric to adult providers, and strengthening coordinated, patient- and family-centered care through a medical home approach.
Why is the pediatric-to-adult transition specifically emphasized?
The announcement describes the transition from pediatric to adult health care providers as a high-risk gap for people living with SCD. Programs are expected to address continuity of care during transitions to reduce breaks in care and improve long-term management.
What does "medical home" mean in this program?
Medical home refers to care that is coordinated, patient- and family-centered, and connected to appropriate specialty services, rather than fragmented across multiple unconnected providers and settings. The program emphasizes strengthening this approach to improve continuity and coordination for people with SCD and other hemoglobinopathies.
What collaboration or partnerships does HRSA expect for Project 1?
HRSA emphasizes collaboration and shared leadership across stakeholders. The ideal model includes partnerships among patients, families, and professionals, and links individuals and family groups with state newborn screening programs, community-based organizations, hemoglobinopathy treatment centers, primary care providers, medical home settings, and public health organizations.
What is Project 2 and what does the National Coordination and Evaluation Center (NCEC) do?
Project 2 establishes one National Coordination and Evaluation Center (NCEC) to serve as the national backbone for coordination, implementation support, and evaluation across HRSA-funded programs. The NCEC is intended to help address common post-newborn screening challenges such as timely follow-up, connecting families to accurate information and services, and reducing barriers to needed health and genetic services.
What are the main responsibilities of the NCEC?
The announcement describes four main NCEC responsibilities: (1) increasing hemoglobinopathy knowledge among affected individuals and families from birth across the lifespan and among providers served by the community-based programs; (2) strengthening partnerships between HRSA-funded programs, community organizations, and other relevant partners; (3) supporting outreach and education aimed at emerging populations; and (4) improving the overall quality of hemoglobinopathy services and activities delivered through the HRSA-funded network.
How do Project 1 and Project 2 fit together?
The opportunity is structured as a two-tier system. Project 1 supports community-based demonstration programs that build and test comprehensive, lifespan-oriented care networks. Project 2 supports a single national center that coordinates across the funded programs, strengthens partnerships, increases knowledge, supports outreach to emerging populations, and promotes quality improvement and shared learning.
What type of funding mechanism is this?
This opportunity uses a cooperative agreement mechanism. That generally indicates substantial federal involvement in guiding or partnering on program activities compared with a standard grant.
How much funding was available for the program overall?
HRSA estimated total program funding at $3,500,000.
What is the expected award size?
Individual awards were expected to range from a floor of $100,000 to a ceiling of $700,000.
Is cost sharing or matching required?
No. The announcement states that cost sharing or matching is not required.
What CFDA program is associated with this opportunity?
The opportunity fell under CFDA 93.110 (Maternal and Child Health Federal Consolidated Programs).
When was the opportunity posted and when did it close?
HRSA posted the opportunity on November 20, 2010. The application closing date was January 18, 2011. The opportunity was later archived on March 19, 2011.
Who was eligible to apply?
Eligibility was described broadly under 42 CFR Part 51a.3(a): any public or private entity, including Indian tribes or tribal organizations, could apply. The announcement also encouraged community-based and faith-based organizations to apply if they could contribute to HRSA's objectives. The summary notes that additional eligibility requirements were included in the application materials.
Are there project-specific eligibility expectations?
Yes. The summary describes capacity expectations for each project. For Project 1, eligible entities are described as national organizations with the capacity, expertise, and knowledge of SCD and other hemoglobinopathies to support HRSA-funded grantees using a life course approach. For Project 2, eligible entities must have the capacity and expertise to deliver a life course approach for affected individuals and families.
Is anyone explicitly not eligible to apply?
Yes. Programs already receiving funding under the Sickle Cell Disease Treatment Demonstration Program (SCDTDP) were not eligible to apply, to prevent duplication and keep the initiative focused on new or distinct capacity.
What is the overall intended impact of the program?
The intended impact is a more reliable, connected pathway from newborn screening through ongoing care, with deliberate attention to counseling, education, access, and practical barriers that can prevent families and providers from getting the right services at the right time, especially in emerging populations.
Browse more opportunities from the same category: Health
Next opportunity: LITERACY, LANGUAGE AND LEARNING EARLY LITERACY AND NUMERACY INITIATIVE
Previous opportunity: School Mental Health Program and Policy Analysis Center
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for HRSA 11 031
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (HRSA 11 031) also looked into and applied for these:
| Funding Opportunity |
|---|
| Reducing New HIV Infections, Strengthening Health And Strategic Information Systems, Capacity Building And Increasing Access To Quality HIV/AIDS Services Through Support Programs Conducted By The Government Of Botswana Under PEPFAR Apply for CDC RFA GH11 1197 Funding Number: CDC RFA GH11 1197 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $23,000,000 |
| Centers without Walls for Collaborative Research in the Epilepsies Genetics and Genomics of Human Epilepsies (U01) Apply for RFA NS 11 007 Funding Number: RFA NS 11 007 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIH Basic Behavioral and Social Science Opportunity Network (OppNet) Short term Mentored Career Development Awards in the Basic Behavioral and Social Sciences for Mid career and Senior Investigators (K18) Apply for RFA DE 11 003 Funding Number: RFA DE 11 003 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NEI Genomic Research Grant on Integrative Data Analysis for Vision Research (R01) Apply for RFA EY 11 001 Funding Number: RFA EY 11 001 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Genetics in Primary Care Apply for HRSA 11 136 Funding Number: HRSA 11 136 Agency: Health Resources and Services Administration Category: Health Funding Amount: $600,000 |
| Maternal Vitamin D Status and Preterm Birth Apply for RFA DP 11 002 Funding Number: RFA DP 11 002 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $225,000 |
| EMSC National Resource Center Apply for HRSA 11 059 Funding Number: HRSA 11 059 Agency: Health Resources and Services Administration Category: Health Funding Amount: $1,900,000 |
| Advanced Education Nursing Traineeship Apply for HRSA 11 043 Funding Number: HRSA 11 043 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Affordable Care Act (ACA) Teaching Health Center (THC) Graduate Medical Education (GME) Payment Program Apply for HRSA 11 149 Funding Number: HRSA 11 149 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Nationwide Program for National and State Background Checks for Direct Patient Access Employees of Long Term Care Facilities and Providers Apply for CMS 1E0 11 001 Funding Number: CMS 1E0 11 001 Agency: Centers for Medicare Medicaid Services Category: Health Funding Amount: $3,000,000 |
| Pregnancy Risk Assessment Monitoring System (PRAMS) (U01) Apply for RFA DP 11 001 Funding Number: RFA DP 11 001 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $200,000 |
| HIV Early Intervention Services (EIS) Program Existing Geographic Service Areas (EISEGA) Apply for HRSA 11 091 Funding Number: HRSA 11 091 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Longitudinal Study of a Population based Cohort of People with Lupus (U01) Apply for RFA DP 11 004 Funding Number: RFA DP 11 004 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $750,000 |
| Surveillance Program Announcement Behavioral Risk Factor Surveillance System Apply for CDC RFA SO11 1101 Funding Number: CDC RFA SO11 1101 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Johnston County Osteoarthritis Project (U01) Apply for RFA DP 11 005 Funding Number: RFA DP 11 005 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $750,000 |
| Surveillance Program Announcement Behavioral Risk Factor Surveillance System (Pacific Jurisdictions) Apply for CDC RFA SO11 1102 Funding Number: CDC RFA SO11 1102 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Nurse Anesthetist Traineeships (NAT) Apply for HRSA 11 044 Funding Number: HRSA 11 044 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| NIAID Resource Related Research Projects for AIDS, Allergy, Immunology and Transplantation (R24) Apply for PAR 11 056 Funding Number: PAR 11 056 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Production of Affinity Reagents for Human Transcription Factors (U54) Apply for RFA RM 10 017 Funding Number: RFA RM 10 017 Agency: National Institutes of Health Category: Health Funding Amount: $2,600,000 |
| Technology Development for New Affinity Reagents Against the Human Proteome (U54) Apply for RFA RM 10 018 Funding Number: RFA RM 10 018 Agency: National Institutes of Health Category: Health Funding Amount: $1,000,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "HRSA 11 031", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.